SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as President Trump's threats of new tariffs on European nations over Greenland escalate geopolitical tensions, leading to a risk-off market sentiment. The community is divided, with some anticipating a significant market pullback, while others view it as a 'buy the dip' opportunity, also noting a Japan-led bond sell-off as a contributing factor. This environment is fueling discussions about broader market volatility and a flight to safe-haven assets.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following constructive discussions with the FDA regarding a resubmission path for ANKTIVA in bladder cancer, complemented by significant international approvals and strategic partnerships like those recently established in Saudi Arabia for broader cancer indications. This development, coupled with high short interest, is fueling widespread community excitement about a potential paradigm shift in oncology and intense speculation regarding a short squeeze amidst growing calls for expedited access to these innovative treatments.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is a major talking point following its J.P. Morgan conference appearance, where investors are eagerly seeking clarity on its strategy for advancing the Matrix-M adjuvant technology and securing new collaborations. Community sentiment is sharply focused on management's pace in realizing pipeline potential, including a recent Pfizer agreement and ongoing Sanofi ventures, with an activist investor's growing stake and significant short interest adding to the intense market watch.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is actively trending amid escalating US-EU trade tensions driven by President Trump's tariff threats over Greenland, sparking a widespread market sell-off and global risk-off sentiment. The investment community is sharply divided between those anticipating a deeper correction for technology and growth stocks and fervent "buy the dip" proponents. Immediate market focus remains on an upcoming Supreme Court ruling regarding tariff authority and a heavy week of earnings reports, amplifying uncertainty.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is seeing heightened conversation due to recent developments surrounding Trump's assertive stance on Greenland and reactions to a perceived Nobel Peace Prize snub, which has sparked discussions of new tariffs on European nations. The community is actively debating the potential for increased market volatility, geopolitical instability, and the broader economic ramifications of these actions. This ongoing dialogue underscores intense political polarization and its influence on market sentiment.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is trending due to a significant surge in natural gas futures, driven by widespread forecasts for severe arctic cold fronts across the US, intensifying heating demand expectations. The community is actively debating the potential for a powerful short squeeze amidst historically high short interest, while also acknowledging the inherent volatility and decay of leveraged natural gas ETFs like $BOIL, often referred to as a "widow maker". Discussions highlight the impact of this weather event on depleting storage levels, yet some remain cautious, pointing to broader warm winter trends and structural factors like contango, questioning the rally's sustainability.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin (APP) is actively trending amid recent allegations of money laundering and illicit financial ties, triggering a sharp sell-off across the stock. Despite this, community sentiment is divided, with many dismissing the claims as a coordinated short attack ahead of strong earnings, while others are seizing the opportunity to buy into the fundamentally strong AI-powered ad platform.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending after announcing positive data from its placebo-controlled Phase 1 clinical trial of soquelitinib for atopic dermatitis, showing strong efficacy. The community is actively discussing the oral ITK inhibitor's potential in a large market, with many anticipating significant revaluation and partnership opportunities for its novel mechanism of action.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is generating significant buzz following a substantial upward revision to its future revenue outlook and a surging order backlog, further bolstered by a recent large capital raise. The community is actively discussing its promising potential as a rapidly expanding defense and autonomy platform, especially amidst ongoing negotiations for key acquisitions in the critical drone technology sector.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors react to a significant patent extension for its key products until 2041, coupled with a bullish preliminary business update accelerating IBSRELA's path to $1 billion in revenue by 2029 and multiple analyst price target upgrades. The community is buzzing with renewed acquisition speculation and optimism over the company's long-term value, despite ongoing discussions about short-term price fluctuations attributed to market dynamics. This confluence of positive developments has many viewing Ardelyx as a significantly undervalued biotech with strong commercial execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alumis (NASDAQ:ALMS) Stock Price Up 6.6% Following Insider Buying Activity

Alumis (NASDAQ:ALMS) Stock Price Up 6.6% Following Insider Buying Activity...

Wednesday 1/14 Insider Buying Report: ALMS, SPT

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. On...

Insider Buying: Alumis (NASDAQ:ALMS) Director Acquires 411,764 Shares of Stock

Alumis Inc. (NASDAQ:ALMS - Get Free Report) Director James Tananbaum purchased 411,764 shares of the company's stock in a transaction dated Thursday, January 8th. The stock was purchased at an...

Alumis (NASDAQ:ALMS) Major Shareholder Buys $6,999,988.00 in Stock

Alumis Inc. (NASDAQ:ALMS - Get Free Report) major shareholder Foresite Capital Management Vi bought 411,764 shares of the stock in a transaction on Thursday, January 8th. The shares were acquired at...

What's Going On With Alumis Stock Thursday?

Alumis Inc. is drawing attention with a major share sale and bullish analyst forecasts. The firm aims to fund its immune disease pipeline.read more...

<ul class="summary-bullets"><li>Investors turned cautious ahead of key U.S. jobs data and a potential court ruling on President Donald Trump’s global tariffs expected Friday.&nbsp;</li><li>Retail traders, however, stayed bullish on SPY and QQQ on Stocktwits.</li></ul>U.S. stock futures were lower early Thursday, following a pullback in major indexes. President&nbsp;Donald Trump’s policy comments triggered a late selloff, with defense, financial, and energy stocks under pressure.Investors are also cautious ahead of the big jobs data and the potential US court&nbsp;ruling on Trump’s global tariffs due on Friday.&nbsp;As of 3:00 a.m. ET on Thursday, Nasdaq 100 futures were down 0.3%, S&amp;P 500 futures and Dow futures were down 0.2%, while Russell 2000 futures fell 0.4%.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘bullish’. While sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has moved back to ‘bullish’ from ‘extremely bullish’ a day ago, amid high message volumes.<h2 class="st-heading-2">Trending Stocks To Watch</h2>Nvidia (NVDA): The Jensen Huang-led chipmaker is reportedly requiring full upfront payment, with&nbsp;no cancellation rights, for H200 chips from Chinese clients to hedge against regulatory export uncertainty. Microsoft (MSFT): The company’s communications&nbsp;chief took to social media to <a href="https://stocktwits.com/news-articles/markets/equity/microsoft-stock-in-focus-as-fresh-layoff-rumors-swirl/cmUGzFNR4PB">blast rumors</a> of fresh mass layoffs as "100% made up," attempting to steady the stock ahead of the&nbsp;market open. Apple (AAPL):&nbsp;Google parent Alphabet (GOOGL) surpassed Apple in market cap for the first time since 2019, closing at $3.888 trillion on Wednesday. It has also switched its banking partner from Goldman Sachs to JPMorgan, the new issuer of the Apple Card.&nbsp; Nio (NIO):&nbsp;The EV maker announced aggressive 2026 expansion plans for Australia, New Zealand, and Thailand, focusing on right-hand-drive markets to bypass Western tariffs. Applied Digital (APLD)&nbsp;saw a high volume of trading following its massive revenue growth report. Ventyx Biosciences (VTYX):&nbsp;Clear Street analyst downgraded the stock to ‘Hold’ from ‘Buy’ with a price target of $14, up from $11, after Eli Lilly (LLY) agreed to acquire Ventyx for $1.2B. Also, LifeSci Capital downgraded it to ‘Market Perform’ from ‘Outperform’ with a $14 price target.&nbsp; Alumis (ALMS) remains on retail radar following a massive ‘follow-on’ financing move following its recent clinical success. Alumis priced an&nbsp;upsized public offering of 17.65 million shares at&nbsp;$17 per share, aiming to raise&nbsp;$300 million. Elevai Labs (ELAB) popped 8%, and&nbsp;Omeros (OMER) rose 5% in after-hours trading on Wednesday, with Omeros gaining steam following a positive FDA conference call on its drug Yartemlea. U.S. defence stocks will be in focus, driven by&nbsp;Trump’s comments to bump up the military budget.Other noteworthy tickers trending on Stocktwits at the time of writing were&nbsp;One Stop Systems (OSS), Paramount Skydance (PSKY), IREN Limited (IREN), Momentus (MNTS), and Regencell Bioscience (RGC).Other Catalysts To Watch On the economic front, investors are looking ahead to the release of Initial Jobless Claims (8:30 a.m. ET), which is a crucial indicator ahead of Friday’s big employment report. Traders will also be monitoring the U.S. Trade Deficit &amp; Productivity data (8:30 a.m. ET) and Consumer Credit data (3 p.m. ET) later today.&nbsp; And noteworthy names on the earnings calendar today include Tilray Brands (TLRY), TD Synnex (SNX),&nbsp;Commercial Metals Company (CMC), and&nbsp;Neogen Corporation (NEOG), among others.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today

Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.

Equity

Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.


ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.

<ul class="summary-bullets"><li>Fed’s Michelle Bowman is also set to speak later in the day.</li><li>On the earnings calendar, notable names reporting include Applied Digital (APLD), Constellation Brands (STZ), Albertsons (ACI), and Cal-Maine Foods (CALM).</li></ul>U.S. stock futures were little changed early Wednesday as investors positioned ahead of key economic data and Fed commentary. Traders are watching for the December ADP employment and ISM Services PMI data, both due later today.As of 3:40 a.m. ET on Wednesday, Nasdaq 100 futures were down 0.2%, S&amp;P 500 and Dow futures were flat, while Russell 2000 futures gained 0.1%.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘bullish’. While sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has flipped to ‘extremely bullish’ from ‘bullish’, amid high message volumes.Trending Stocks To Watch Nvidia (NVDA): CEO Jensen Huang has flagged ‘very high’ China demand for H200 chips and added that the company is working with the US government on final export license details. Meta (META): Chinese officials are reportedly reviewing Meta’s acquisition of Singapore-based AI firm Manus to assess whether the transfer of Chinese-origin AI tech required an export license. Applied Digital (APLD) is among the top-trending tickers on Stocktwits ahead of its earnings report today.&nbsp;Ventyx Biosciences (VTYX):&nbsp;Stock surged after hours following reports that Eli Lilly is nearing a $1B+ acquisition. A whole host of memory chip stocks, including SanDisk (SNDK), Western Digital (WDC), Micron (MU), and Seagate (STX), hit new highs amid&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sandisk-wdc-seagate-which-memory-stock-is-the-better-bet/cmxyrKqR4cK">concerns</a> over a critical shortage of memory-making machinery. Amazon (AMZN) is gaining retail attention amid reports that traders have pushed back against its AI shopping tool, alleging it scraped product data without consent.&nbsp; MobilEye Global (MBLY): Stock gained after-hours after agreeing to buy Mentee Robotics in a cash-and-stock deal.&nbsp; Oil stocks (CVX, EXOM) remain in focus President Trump announced interim Venezuelan authorities will transfer 30M–50M barrels of oil to the US, causing Brent crude to slide toward $57-$60/bbl. Alumis (ALMS) remains on retail radar following&nbsp;its Phase 3 psoriasis trial results, which prompted multiple analysts to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alumis-stock-hits-record-high-as-wall-street-cheers-phase-3-psoriasis-win-analysts-see-best-in-class-potential/cmxynYnR4cB">raise price targets</a> and reiterate bullish ratings on the stock. Other noteworthy tickers trending on Stocktwits at the time of writing were&nbsp;Terrestrial Energy (IMSR), Critical Metals Corp (CRML), and Regencell Bioscience (RGC). Other Catalysts To Watch On the economic front, investors are looking ahead to the release of December ADP employment figures, scheduled for 8:15 a.m. ET, setting the tone ahead of official payrolls. The ISM Services PMI data is due at 10:00 am ET.&nbsp; Fed Vice Chair for Supervision Michelle Bowman is scheduled to speak later in the day. And noteworthy names on the earnings calendar today include Applied Digital (APLD), Constellation Brands (STZ), Albertsons Companies (ACI), and Cal-Maine Foods (CALM), among others. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Tread Water Ahead Of ADP Data: Why NVDA, META, APLD, VTYX, ALMS Are On Traders' Radar Today

Nvidia, memory-chip stocks, and AI-linked names dominated chatter ahead of data and earnings.

<ul class="summary-bullets"><li>Analysts lifted price targets and reaffirmed bullish ratings after the Phase 3 results.</li><li>The new trial data showed strong skin clearance with results improving over time.</li><li>Alumis outlined plans for an FDA filing in 2026.</li></ul>Shares of Alumis Inc. hit a record high after Wall Street responded positively to the company’s Phase 3 psoriasis trial results, prompting multiple analysts to raise price targets and reiterate bullish ratings on the stock.The rally followed Alumis’ announcement of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-alms-stock-rising-today/cmxwvW3R4Tk">positive topline data from its Phase 3 Onward program</a> evaluating Envudeucitinib in patients with moderate-to-severe plaque psoriasis.<a href="https://stocktwits.com/symbol/ALMS">Alumis’ stock</a> surged over 95% on Tuesday to $16.23, and added another 3% in after hours trading.&nbsp;<h2 class="st-heading-2">Leerink, Oppenheimer Raise Targets After Trial ‘Win’</h2>Following the data, Leerink Partners raised its price target on Alumis to $32 from $20 and maintained an ‘Outperform’ rating, implying upside of about 100% from the stock’s last close.The firm said the strong topline results and additional details from the investor call reinforced Envudeucitinib’s favorable clinical profile and reignited strategic optionality around what it described as a “potentially best-in-class” Tyrosine Kinase 2 (TYK2) franchise, calling the outcome a clear “win.”Separately, Oppenheimer raised its price target to $50 from $25 and reiterated an ‘Outperform’ rating, implying upside of about 212% from the stock’s last close. Analyst Jeff Jones said Envudeucitinib appears “highly competitive and potentially superior to Icotrokinra on some endpoints” following the trial results.<h2 class="st-heading-2">Phase 3 Data Shows High Levels Of Skin Clearance</h2>Alumis said Envudeucitinib met all primary and secondary endpoints in both Onward1 and Onward2 trials with high statistical significance. By 16 weeks, 74% of patients saw major improvement in their psoriasis, and nearly 60% had skin that was clear or almost clear across the two studies.By 24 weeks, Alumis said about two-thirds of patients saw near-complete clearing of their psoriasis, while more than 40% had completely clear skin. The company also said Envudeucitinib performed better than the standard treatment across all key measures of skin improvement at that point in the trial.The company said treatment was generally well tolerated through Week 24, with a safety profile consistent with its Phase 2 program and no new safety signals observed.<h2 class="st-heading-2">Regulatory Timeline</h2>Alumis said it plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026 and expects to present additional Onward data at an upcoming medical meeting.Envudeucitinib is also being tested as a potential treatment for lupus, another autoimmune disease, with topline data from the Phase 2b Lumus trial expected in the third quarter of 2026.After releasing the Phase 3 data, Alumis announced plans for an underwritten public offering of $175 million of common stock, with an option for underwriters to purchase additional shares.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Alumis was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/alms_ss_png_ddce06f504.webp" alt="alms ss.png" width="971" height="143"><figcaption>ALMS sentiment and message volume as of January 6| Source: Stocktwits</figcaption></figure>One user said the company has no debt, ample cash on hand, and a positive long-term outlook.<stembedurl>https://stocktwits.com/prohibited/message/641002483</stembedurl>Another user said they expect the stock to hold above $16 after the offering, move gradually toward the $18–$20 range, and then potentially pull back afterward.<stembedurl>https://stocktwits.com/Donniechen12345/message/641021469</stembedurl><a href="https://stocktwits.com/symbol/ALMS">Alumis’ stock</a> has risen 92% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alumis logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential

The company also disclosed plans of a $175 million underwritten share offering after releasing its Phase 3 trial data.

Sandisk, Alumis, Micron Technology, Ventyx Biosciences, And Western Digital: Why These 5 Stocks Are On Investors' Radars Today

SNDK, ALMS, MU, VTYX, WDC were among the stocks seen trending among investors on Tuesday, Jan. 6, 2026.read more...

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

ALMS
Alumis Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALMS News

ALMSAlumis Inc.